Author

Matthew R. Smith

Observed names: M Smith, M. Smith, Matthew Smith

Institutions: Harvard University, Massachusetts General Hospital

Observed institutions: University Hospitals Birmingham NHS Foundation Trust, Harvard University, Queen Elizabeth Hospital Birmingham, Massachusetts General Hospital

ORCID: 0000-0002-5983-8989

Observed ORCID: 0000-0002-5983-8989

OpenAlex ID: A5101655026

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

2024 · Silke Gillessen, Fabio Turco, et al. · European Urology · 171

Non‐destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T

2001 · Leo Ling Cheng, Chin-lee Wu, et al. · FEBS Letters · 159

Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma

2005 · Hang Lee, Katelyn McGovern, et al. · Cancer · 148

PDF

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

2022 · Silke Gillessen, Alberto Bossi, et al. · European Urology · 133

Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.

2008 · H H Malluche, G A Siami, et al. · PubMed · 92

Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases

2018 · Matthew Evans, Brendan O’Sullivan, et al. · Pathology & Oncology Research · 39

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer

2016 · Jérôme Solassol, Julie Vendrell, et al. · PLoS ONE · 37

PDF

Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we?

2018 · Matthew Evans, Brendan O’Sullivan, et al. · Translational Lung Cancer Research · 35

PDF

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer

2018 · Iván Prieto-Potin, Clara Montagut, et al. · Journal of Molecular Diagnostics · 25

Multicenter Evaluation of the Idylla GeneFusion in Non–Small-Cell Lung Cancer

2022 · Thomas Depoilly, Simon Garinet, et al. · Journal of Molecular Diagnostics · 19

PDF

Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

2024 · Wassim Abida, Andrew W. Hahn, et al. · Clinical Cancer Research · 18

PDF

Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study

2024 · Manuel Weber, Wolfgang P. Fendler, et al. · European Urology · 14

Microscopic gastrointestinal stromal tumours: a clinical and molecular study of 13 cases

2016 · William Anderson, Brendan O'Sullivan, et al. · Histopathology · 12

Low bone mineral density in hormone‐naïve men with prostate carcinoma

2001 · Matthew R. Smith, Francis J. McGovern, et al. · Cancer · 6

The association between PD-L1 expression, EGFR mutation and ALK translocation in a series of 982 lung cancers

2017 · M. Evans, B. O'Sullivan, et al. · Annals of Oncology · 4

1307P The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice

2023 · L. Robertson, P. Taniere, et al. · Annals of Oncology · 1

PDF

Data from Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

2023 · Wolfgang P. Fendler, Manuel Weber, et al. · 1

Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022]

2022 · Martin Bögemann, Neal D. Shore, et al. · European Urology · 1

PDF

Mp27-05 Efficacy and Safety of Darolutamide in Nonmetastatic Castration-resistant Prostate Cancer Patients With and Without Prior Local Therapy With Radical Prostatectomy or Radiotherapy

2022 · David Robert Siemens, Karim Fizazi, et al. · The Journal of Urology · 1

Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial

2026 · Brigida A. Maiorano, Matthew R. Smith, et al. · European Journal of Cancer

Data from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide